Cargando…
Modeling the impact of delaying transcatheter aortic valve replacement for the treatment of aortic stenosis in the era of COVID-19
OBJECTIVE: The aim of this study was to model the short term and 2-year overall survival (OS) for intermediate-risk and low-risk patients with severe symptomatic aortic stenosis (AS) undergoing timely or delayed transcatheter aortic valve replacement (TAVR) during the 2019 novel coronavirus (COVID-1...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8184875/ https://www.ncbi.nlm.nih.gov/pubmed/34124697 http://dx.doi.org/10.1016/j.xjon.2021.06.006 |
_version_ | 1783704668434595840 |
---|---|
author | Freno, Daniel R. Shipe, Maren E. Levack, Melissa M. Shah, Ashish S. Deppen, Stephen A. O'Leary, Jared M. Grogan, Eric L. |
author_facet | Freno, Daniel R. Shipe, Maren E. Levack, Melissa M. Shah, Ashish S. Deppen, Stephen A. O'Leary, Jared M. Grogan, Eric L. |
author_sort | Freno, Daniel R. |
collection | PubMed |
description | OBJECTIVE: The aim of this study was to model the short term and 2-year overall survival (OS) for intermediate-risk and low-risk patients with severe symptomatic aortic stenosis (AS) undergoing timely or delayed transcatheter aortic valve replacement (TAVR) during the 2019 novel coronavirus (COVID-19) pandemic. METHODS: We developed a decision analysis model to evaluate 2 treatment strategies for both low-risk and intermediate-risk patients with AS during the COVID-19 novel coronavirus pandemic. RESULTS: Prompt TAVR resulted in improved 2-year OS compared with delayed intervention for intermediate-risk patients (0.81 vs 0.67) and low-risk patients (0.95 vs 0.85), owing to the risk of death or the need for urgent/emergent TAVR in the waiting period. However, if the probability of acquiring COVID-19 novel coronavirus is >55% (intermediate-risk patients) or 47% (low-risk patients), delayed TAVR is favored over prompt intervention (0.66 vs 0.67 for intermediate risk; 0.84 vs 0.85 for low risk). CONCLUSIONS: Prompt transcatheter aortic valve replacement for both intermediate-risk and low-risk patients with symptomatic severe AS results in improved 2-year survival when local healthcare system resources are not significantly constrained by the COVID-19. |
format | Online Article Text |
id | pubmed-8184875 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-81848752021-06-08 Modeling the impact of delaying transcatheter aortic valve replacement for the treatment of aortic stenosis in the era of COVID-19 Freno, Daniel R. Shipe, Maren E. Levack, Melissa M. Shah, Ashish S. Deppen, Stephen A. O'Leary, Jared M. Grogan, Eric L. JTCVS Open Adult: Aortic Valve OBJECTIVE: The aim of this study was to model the short term and 2-year overall survival (OS) for intermediate-risk and low-risk patients with severe symptomatic aortic stenosis (AS) undergoing timely or delayed transcatheter aortic valve replacement (TAVR) during the 2019 novel coronavirus (COVID-19) pandemic. METHODS: We developed a decision analysis model to evaluate 2 treatment strategies for both low-risk and intermediate-risk patients with AS during the COVID-19 novel coronavirus pandemic. RESULTS: Prompt TAVR resulted in improved 2-year OS compared with delayed intervention for intermediate-risk patients (0.81 vs 0.67) and low-risk patients (0.95 vs 0.85), owing to the risk of death or the need for urgent/emergent TAVR in the waiting period. However, if the probability of acquiring COVID-19 novel coronavirus is >55% (intermediate-risk patients) or 47% (low-risk patients), delayed TAVR is favored over prompt intervention (0.66 vs 0.67 for intermediate risk; 0.84 vs 0.85 for low risk). CONCLUSIONS: Prompt transcatheter aortic valve replacement for both intermediate-risk and low-risk patients with symptomatic severe AS results in improved 2-year survival when local healthcare system resources are not significantly constrained by the COVID-19. Elsevier 2021-06-08 /pmc/articles/PMC8184875/ /pubmed/34124697 http://dx.doi.org/10.1016/j.xjon.2021.06.006 Text en © 2021 The Authors. Published by Elsevier Inc. on behalf of The American Association for Thoracic Surgery. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Adult: Aortic Valve Freno, Daniel R. Shipe, Maren E. Levack, Melissa M. Shah, Ashish S. Deppen, Stephen A. O'Leary, Jared M. Grogan, Eric L. Modeling the impact of delaying transcatheter aortic valve replacement for the treatment of aortic stenosis in the era of COVID-19 |
title | Modeling the impact of delaying transcatheter aortic valve replacement for the treatment of aortic stenosis in the era of COVID-19 |
title_full | Modeling the impact of delaying transcatheter aortic valve replacement for the treatment of aortic stenosis in the era of COVID-19 |
title_fullStr | Modeling the impact of delaying transcatheter aortic valve replacement for the treatment of aortic stenosis in the era of COVID-19 |
title_full_unstemmed | Modeling the impact of delaying transcatheter aortic valve replacement for the treatment of aortic stenosis in the era of COVID-19 |
title_short | Modeling the impact of delaying transcatheter aortic valve replacement for the treatment of aortic stenosis in the era of COVID-19 |
title_sort | modeling the impact of delaying transcatheter aortic valve replacement for the treatment of aortic stenosis in the era of covid-19 |
topic | Adult: Aortic Valve |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8184875/ https://www.ncbi.nlm.nih.gov/pubmed/34124697 http://dx.doi.org/10.1016/j.xjon.2021.06.006 |
work_keys_str_mv | AT frenodanielr modelingtheimpactofdelayingtranscatheteraorticvalvereplacementforthetreatmentofaorticstenosisintheeraofcovid19 AT shipemarene modelingtheimpactofdelayingtranscatheteraorticvalvereplacementforthetreatmentofaorticstenosisintheeraofcovid19 AT levackmelissam modelingtheimpactofdelayingtranscatheteraorticvalvereplacementforthetreatmentofaorticstenosisintheeraofcovid19 AT shahashishs modelingtheimpactofdelayingtranscatheteraorticvalvereplacementforthetreatmentofaorticstenosisintheeraofcovid19 AT deppenstephena modelingtheimpactofdelayingtranscatheteraorticvalvereplacementforthetreatmentofaorticstenosisintheeraofcovid19 AT olearyjaredm modelingtheimpactofdelayingtranscatheteraorticvalvereplacementforthetreatmentofaorticstenosisintheeraofcovid19 AT groganericl modelingtheimpactofdelayingtranscatheteraorticvalvereplacementforthetreatmentofaorticstenosisintheeraofcovid19 |